Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022-Reference-Cited by-同舟云学术

Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022

Published:2023 Issue:27 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Kim Jong Mu¹^ORCID,Yoo Min-Gyu¹^ORCID,Bae Soon Jong¹²^ORCID,Kim Jungyeon¹²^ORCID,Lee Hyungmin¹²^ORCID

Affiliation:

1. Patient Management Team, Central Disease Control Headquarters for COVID-19, Korea Disease Control and Prevention Agency, Cheongju, Korea.

2. Division of Emerging Infectious Disease, Bureau of Infectious Disease Risk Response, Korea Disease Control and Prevention Agency, Cheongju, Korea.

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2023.38.e211

Reference35 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. The novel coronavirus outbreak in Wuhan, China

3. World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. Updated 2021. Accessed November 26, 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

4. The rapid and efficient strategy for SARS-CoV-2 Omicron transmission control: analysis of outbreaks at the city level

5. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study;BMC Infectious Diseases;2024-09-03

2. Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2, Update Alert);Annals of Internal Medicine;2024-08

3. Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico;Journal of Infection and Public Health;2024-07

4. Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study;Osong Public Health and Research Perspectives;2024-04-30

5. Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review;Advances in Respiratory Medicine;2024-01-18